Emphasys On The Block After FDA Panel Rejection Of Pulmonary Valve
This article was originally published in The Gray Sheet
Executive Summary
The end is near for Emphasys Medical. At the end of March, the company's ongoing business and assets will be put up for auction, serving as a disappointing end to the firm's nine-year effort to get its Zephyr Endobronchial Valve to market
You may also be interested in...
US Market In Pulmonx' Sights Nine Years After Zephyr First Failure
Pulmonx is almost ready to submit the results of the pivotal LIBERATE trial of its Zephyr endobronchial valve to the US FDA. The data will support a premarket approval and the company hopes to bring the device, along with the Chartis patient-selection system, to the US market in 2018.
Pulmonx Reaches Multiple Milestones In Lung-Valve, Diagnostics Development
Encouraging results from the IMPACT study of Pulmonx's Zephyr endobronchial valve in patients with homogenous emphysema – a population with almost no other options – is the latest in string of good news for the Silicon Valley company, which wants to create a new paradigm of personalized device therapy for pulmonary disease.
Despite Setbacks, Emphysema Devices Find Funding
Minimally invasive emphysema devices have seen their ups and downs over the years, but despite technological and regulatory challenges, VCs continue to fund these devices, with investments driven by the market opportunity, huge unmet clinical need, and promising technologies.